Nasvax

Nasvax is a pioneering biotechnology company dedicated to the development of improved vaccines and immunotherapeutic products. With a focus on innovation, Nasvax operates across four distinct product areas: oral anti-CD3 monoclonal antibody immunotherapeutic, VaxiSome® technology (an adjuvant-delivery system designed to enhance the immunogenicity of vaccines and immunotherapeutics), a group-common pneumococcal vaccine (a protein-based vaccine poised to become the field’s third-generation product), and BBS1-based immunotherapeutics for Alzheimer’s disease.

Located at 18 Einstien St. Kiryat Weizmann, Science Park, P.O.B 4122, Ness Zionna, 74140, IL, Nasvax is committed to advancing healthcare through cutting-edge research and development. The company's diverse portfolio reflects its dedication to addressing significant medical challenges and improving patient outcomes. Nasvax continues to explore new avenues in biotechnology, solidifying its position as a leader in the industry.

Nasvax is focused on expanding its reach and impact. We invite the manager of Nasvax to create a customized and exclusive company showcase and product listing on our platform to further enhance its visibility and commercial opportunities.